Issue Date: December 8, 2008
... As Suppliers Shift Offerings
Introgen Therapeutics is reorganizing to focus on its Houston-based manufacturing and service business, Introgen Technical Services. The firm has declared bankruptcy and will cut about 30 of its 45 employees. A few employees will continue to support regulatory filings for the company's anticancer therapy Advexin. Meanwhile, in the face of lower demand from small biotech firms, Wuxi PharmaTech says it will cease biologics manufacturing at its Philadelphia site, eliminating about 100 jobs, and instead devote the facility to biologics testing and cell services.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society